Gilead Sciences, Inc.
145.65USD
-0.9900 (-0.68%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,803 | 6,960 | 7,925 | 7,769 | 7,082 | 6,667 | 7,569 | 7,545 |
| Cost of Revenue | 1,579 | 1,445 | 1,624 | 1,569 | 1,501 | 1,540 | 1,581 | 1,574 |
| Gross Profit | 6,224 | 5,515 | 6,301 | 6,200 | 5,581 | 5,127 | 5,988 | 5,971 |
| Operating Income | -10,394 | 2,586 | 1,984 | 3,327 | 2,474 | 2,237 | 2,452 | 888 |
| Net Income | -10,496 | 2,021 | 2,183 | 3,052 | 1,960 | 1,315 | 1,783 | 1,253 |
| EPS (Diluted) | $-8.45 | $1.61 | $1.74 | $2.43 | $1.56 | $1.04 | $1.42 | $1.00 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)